Search
FSD Pharma begins Phase 1 In-Human Safety & Tolerability Study of Ultra Micro-Palmitolylethanolamiode

FSD Pharma begins Phase 1 In-Human Safety & Tolerability Study of Ultra Micro-Palmitolylethanolamiode

Author

InvestmentPitchMedia

Published on March 10, 2020

FSD Pharma Inc., a specialty, biotech pharmaceutical R&D company, focused on developing, over time, a robust pipeline of FDA approved synthetic compounds targeting the endocannabinoid system of the human body, is initiating a new study at the Alfred Hospital in Australia.


Category : News

0 Comments

cmntImg
Auto Play